Ken Griffin Coherus Bio Sciences, Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$0.99 - $1.8 $11,286 - $20,520	-11,400 Reduced 22.4%	39,500 $41,000
Q2 2024 Aug 14, 2024	SELL	$1.58 - $2.51 $54,826 - $87,096	-34,700 Reduced 40.54%	50,900 $88,000
Q1 2024 May 15, 2024	SELL	$2.02 - $3.14 $77,535 - $120,525	-38,384 Reduced 30.96%	85,600 $204,000
Q4 2023 Feb 14, 2024	BUY	$1.59 - $3.85 $110,797 - $268,283	69,684 Added 128.33%	123,984 $412,000
Q3 2023 Nov 14, 2023	BUY	$3.74 - $5.45 $52,734 - $76,845	14,100 Added 35.07%	54,300 $203,000
Q2 2023 Aug 14, 2023	BUY	$3.79 - $8.3 $123,554 - $270,580	32,600 Added 428.95%	40,200 $171,000
Q1 2023 May 15, 2023	SELL	$5.89 - $10.52 $184,946 - $330,328	-31,400 Reduced 80.51%	7,600 $51,000
Q4 2022 Feb 14, 2023	BUY	$5.69 - $10.07 $221,910 - $392,730	39,000 New	39,000 $308,000

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $85.5M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.